### Cyclophosphamide

**Indication**
Chronic lymphocytic leukaemia or small lymphocytic lymphoma

**INN**
Cyclophosphamide

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg

**EML status history**
- First added in 1977 ([TRS 615](https://www.who.int/medicines/publications/essentialmedicines/1977/TRS_615))
- Changed in 2015 ([TRS 994](https://www.who.int/medicines/publications/essentialmedicines/2015/TRS_994))
- Changed in 2019 ([TRS 1021](https://www.who.int/medicines/publications/essentialmedicines/2019/TRS_1021))
- Changed in 2021 ([TRS 1035](https://www.who.int/medicines/publications/essentialmedicines/2021/TRS_1035))
- Changed in 2022 ([TRS 1049](https://www.who.int/medicines/publications/essentialmedicines/2022/TRS_1049))

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Cyclophosphamide

**DrugBank**
Cyclophosphamide

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for oral dosage forms of cyclophosphamide on the EML and EMLc be amended to replace 'tablet' with 'solid oral dosage form' to reflect the availability also of capsules and allow greater flexibility in procurement.

[Expert Committee report](#)